Literature DB >> 30421471

Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study.

Luana Benedetti1, Chiara Briani2, Alessandro Beronio3, Federico Massa1, Elisa Giorli3, Cinzia Sani4, Paola Delia5, Stefania Artioli6, Maria P Sormani7, Antonio Mannironi3, Antonio Tartaglione3, Giovanni L Mancardi1.   

Abstract

Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a worldwide incidence of 0.81-1.89 per 100 000 person-years. In Europe and North America only 5% of patients with GBS have axonal subtypes, which in South America and Asia account for 30%-47% of cases. The aim of our study is to assess the annual incidence and clinical features of GBS in La Spezia area in Italy. A retrospective (from 1 January 2003 to 31 December 2011) followed by a prospective (from 1 January 2012 to 31 December 2015) analysis was carried out on patients admitted to La Spezia hospital who fulfilled the GBS diagnostic criteria. A total of 86 patients (58 men), mean age of 62.7 years (range 21-90), were included. The mean annual incidence rate was 3/100 000 (range: 0.9/100 000-5.37/100 000) significantly higher than the European incidence (P < 0.001). Forty-seven percent were classified as acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 35% as acute motor and motor-sensory axonal neuropathy (AMAN-AMSAN), 13% as variant forms, and 5% were not defined. AIDP was most common in "Golfo dei Poeti" (50%) and "Val di Magra" (63.2%), whereas AMAN/AMSAN prevailed in "Val di Vara" (63.6%) and "Riviera Spezzina" (62.5%) (P = 0.024). In La Spezia area GBS incidence (especially the AMAN subtype) is significantly higher than the incidence reported in Europe. AIDP predominates in the eastern area whereas AMAN/AMSAN in the western, with a significantly different incidence rate (P = 0.003). Prospective studies to assess possible predisposing environmental factors are needed.
© 2018 Peripheral Nerve Society.

Entities:  

Keywords:  AIDP; AMAN; Guillain-Barré syndrome; annual incidence

Mesh:

Year:  2018        PMID: 30421471     DOI: 10.1111/jns.12292

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  3 in total

Review 1.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

Review 2.  Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis.

Authors:  Lina Palaiodimou; Maria-Ioanna Stefanou; Aristeidis H Katsanos; Paraskevi C Fragkou; Marianna Papadopoulou; Christos Moschovos; Ioannis Michopoulos; Panagiotis Kokotis; Christos Bakirtzis; Androniki Naska; Theodoros I Vassilakopoulos; Elisabeth Chroni; Sotirios Tsiodras; Georgios Tsivgoulis
Journal:  Eur J Neurol       Date:  2021-04-28       Impact factor: 6.288

3.  Clinical Features and Outcome of the Guillain-Barre Syndrome: A Single-Center 11-Year Experience.

Authors:  Federica Ginanneschi; Fabio Giannini; Francesco Sicurelli; Carla Battisti; Giorgio Capoccitti; Sabina Bartalini; Andrea Mignarri; Nila Volpi; David Cioncoloni; Laura Franci; Nicola De Stefano; Alessandro Rossi
Journal:  Front Neurol       Date:  2022-06-29       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.